Do tiny coronary blood vessel problems affect outcomes in dilated cardiomyopathy?
Official title: Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07293338 · Data updated 2026-11-12
This project will test whether coronary microvascular dysfunction changes long-term outcomes for people with dilated cardiomyopathy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 330 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | January 6, 2026 |
| Main results expected | November 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT07293338 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with confirmed dilated cardiomyopathy (enlarged LV by echo), clinical heart failure with BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL, LVEF <45%, and coronary angiography showing ≤50% stenosis in all major epicardial vessels.
✕Probably not a fit
Patients with significant coronary artery disease, hypertensive heart disease, rheumatic valvular disease, myocarditis, other secondary cardiomyopathies, or poor angiographic image quality are not expected to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will enroll adults with dilated cardiomyopathy, reduced left ventricular ejection fraction, and no significant epicardial coronary stenosis. Coronary angiography performed for clinical care will be used to characterize coronary microvascular function. Participants will be followed over time for clinical outcomes such as heart failure progression, hospitalizations, biomarkers, and death. The goal is to link baseline microvascular findings to long-term prognosis in this population.
Why it matters
Potential benefit: If successful, the findings could help identify patients at higher risk who may need closer monitoring or targeted therapies.
How similar studies have gone: Some studies in other cardiac conditions have linked microvascular dysfunction to worse outcomes, but its prognostic role specifically in dilated cardiomyopathy is not yet well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Dilated cardiomyopathy comfirmed by echocardiography: LVDd \> 55 mm in men or \> 50 mm in women. * Clinically evident congestive heart failure: Compatible symptoms and signs, and BNP ≥ 35 pg/mL or NT-proBNP ≥ 125 pg/mL, and LV systolic dysfunction defined by LVEF \< 45 %. * Coronary angiography showing stenosis ≤ 50 % in all major epicardial vessels. Exclusion Criteria: * Patients with coronary artery disease, hypertensive heart disease, rheumatic valvular heart disease, myocarditis, and other secondary cardiomyopathies. * poor angiographic image quality
Where it's running
-
The second affiliated hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Jun Jiang, MD
- Email: 21918219@zju.edu.cn
- Phone: +86 15657125311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Second infusion of FAP-targeted iCDC for end-stage dilated cardiomyopathy
This study tests whether a second dose of FAP-targeted immunosuppressive CAR-DC therapy can safely improve heart function in adults with end-stage dilated cardiomyopathy who previously had a partial response.
-
AAV Gene Therapy for BAG3-Related Dilated Cardiomyopathy in Adults
This Phase 1/2 trial tests a single IV dose of AFTX-201 to see if it is safe and potentially helps adults with BAG3-related dilated cardiomyopathy.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Multimodal analysis of heart biopsy samples
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
-
T1 mapping to characterize heart tissue in common heart diseases
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
-
Endocardial delivery of stem-cell derived heart cells to help severe heart failure
This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.